NYSEArca - Delayed Quote USD

VanEck Indonesia Index ETF (IDX)

17.61 +0.13 (+0.74%)
At close: October 15 at 4:00 PM EDT
17.06 -0.55 (-3.12%)
Pre-Market: 9:06 AM EDT
Loading Chart for IDX
DELL
  • Previous Close 17.48
  • Open 17.61
  • Bid 16.58 x 1100
  • Ask 17.73 x 900
  • Day's Range 17.47 - 17.62
  • 52 Week Range 14.94 - 19.10
  • Volume 301,868
  • Avg. Volume 106,460
  • Net Assets 52.27M
  • NAV 17.66
  • PE Ratio (TTM) 8.76
  • Yield 3.43%
  • YTD Daily Total Return 3.16%
  • Beta (5Y Monthly) 0.48
  • Expense Ratio (net) 0.58%

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes securities of Indonesian companies. A company is generally considered to be an Indonesian company if it is incorporated in Indonesia or is incorporated outside of Indonesia but has at least 50% of its revenues/related assets in Indonesia. Such companies may include small- and medium-capitalization companies. It is non-diversified.

VanEck

Fund Family

Miscellaneous Region

Fund Category

52.27M

Net Assets

2009-01-15

Inception Date

Performance Overview: IDX

View More

Trailing returns as of 10/15/2024. Category is Miscellaneous Region.

YTD Return

IDX
3.16%
Category
--
 

1-Year Return

IDX
7.25%
Category
--
 

3-Year Return

IDX
2.96%
Category
--
 

People Also Watch

Holdings: IDX

View More

Top 10 Holdings (53.74% of Total Assets)

SymbolCompany% Assets
BBCA.JK
PT Bank Central Asia Tbk 7.96%
BBRI.JK
PT Bank Rakyat Indonesia (Persero) Tbk 7.70%
BMRI.JK
PT Bank Mandiri (Persero) Tbk 6.52%
TLK
Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk 5.79%
AMMN.JK
PT Amman Mineral Internasional Tbk 4.95%
TPIA.JK
PT Chandra Asri Pacific Tbk 4.83%
ASII.JK
PT Astra International Tbk 4.45%
BBNI.JK
PT Bank Negara Indonesia (Persero) Tbk 4.14%
BREN.JK
PT Barito Renewables Energy Tbk 3.82%
GOTO.JK
PT GoTo Gojek Tokopedia Tbk 3.57%

Sector Weightings

SectorIDX
Energy   8.28%
Industrials   6.77%
Utilities   4.76%
Technology   3.68%
Healthcare   2.77%
Real Estate   1.53%

Related ETF News

View More

Research Reports: IDX

View More
  • Wipro Earnings: Weak Demand for Discretionary IT Services Projects Continues to Affect Financials

    Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.

    Rating
    Price Target
     
  • Infosys Earnings: Macro-Induced Demand Weakness Continues to Weigh Down Results

    Infosys is a leading global IT services provider, with nearly 250,000 employees. Based in Bangalore, the Indian IT services firm leverages its offshore outsourcing model to derive 60% of its revenue from North America. The company offers traditional IT services offerings: consulting, managed services and cloud infrastructure services, and business process outsourcing as a service (BPaaS).

    Rating
    Price Target
     
  • Infosys Earnings: Revenue Guidance Lowered Even After Q2 Beats Our Expectations; Maintain $16 FVE

    Infosys is a leading global IT services provider, with nearly 250,000 employees. Based in Bangalore, the Indian IT services firm leverages its offshore outsourcing model to derive 60% of its revenue from North America. The company offers traditional IT services offerings: consulting, managed services and cloud infrastructure services, and business process outsourcing as a service (BPaaS).

    Rating
    Price Target
     
  • Dr. Reddy’s Earnings: Strong Demand From Developed Markets Fuels Solid Second-Quarter Results

    Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

    Rating
    Price Target
     

Related Tickers